Heart in Hyperthyroidism
Hyperthyroidism is a common endocrine disorder that produces important clinical consequences on the cardiovascular system. In overt hyperthyroidism the increase in left ventricular performance is predominantly sustained by an increased preload with enhanced left ventricular diastolic function and reduced systemic vascular resistance. The pattern of cardiovascular abnormalities is similar in subclinical and overt hypothyroidism, suggesting that a lesser degree of thyroid hormone deficiency may also affect the cardiovascular system. Untreated overt and subclinical hypothyroidism can lead to an increased risk of coronary heart disease (CHD), heart failure (HF), and cardiovascular mortality.
Prompt and effective recognition of cardiac manifestations of hyperthyroidism is crucial as cardiovascular complications account for most of the deaths in hyperthyroid patients. Graves’ disease should be considered in patients with pulmonary hypertension, dilated cardiomyopathy, and peripartum cardiomyopathy of unknown etiology.
Doppler echocardiography is a useful technique to assess cardiovascular complications in hyperthyroid patients with cardiac symptoms. Its use is justified in symptomatic patients as it allows assessment of potential cardiovascular involvement.
Correction of overt and subclinical hyperthyroidism should be the first step in improving the prognosis of hyperthyroid patients with cardiovascular complications.
The etiology of hyperthyroidism must be established to enable correct treatment of the disease and of the related cardiovascular complications.
KeywordsSubclinical hyperthyroidism Overt hyperthyroidism Cardiovascular risk Management Antithyroid drugs Radioactive iodine Surgery
- 8.Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of thyroid hormone on cardiac function: the relative importance of heart rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism. J Clin Endocrinol Metab. 2002;87:968–74.CrossRefGoogle Scholar
- 15.Biondi B, Palmieri EA, Fazio S, Cosco C, Nocera M, Saccá L, Filetti S, Lombardi G, Perticone F. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab. 2000;85:4702–5.Google Scholar
- 19.Hammond HK, White FC, Buxton IL, Saltzstein P, Brunton LL, Longhurst JC. Increased myocardial ß-receptors and adrenergic responses in hyperthyroid pigs. Am J Phys. 1987;252:H283–90.Google Scholar
- 28.Selmer C, Olesen JB, Hansen ML, von Kappelgaard LM, Madsen JC, Hansen PR, Pedersen OD, Faber J, Torp-Pedersen C, Gislason GH. J subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. Clin Endocrinol Metab. 2014;99(7):2372–282.CrossRefGoogle Scholar
- 31.Soh MC, Croxson M. Fatal thyrotoxic cardiomyopathy in a young man. BMJ. 2008;28:337–531.Google Scholar
- 34.Gencer B, Collet TH, Virgini V, Bauer DC, Gussekloo J, Cappola AR, Nanchen D, den Elzen WPJ, Balmer P, Luben RN, Iacoviello M, Triggiani V, Cornuz J, Newman AB, Khaw KT, Jukema JW, RGJ W, Vittinghoff E, Aujesky D, Rodondi N. Thyroid studies collaboration. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from six prospective cohorts. Circulation. 2012;126:1040–9.CrossRefGoogle Scholar
- 35.Biondi B, Fazio S, Carella C, Sabatini D, Amato G, Cittadini A, Bellastella A, Lombardi G, Saccà L. Controls of adrenergic contracticity. Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine. J Clin Endocrinol Metab. 1994;78(5):1028–33.PubMedGoogle Scholar
- 37.Collet TH, Gussekloo J, Bauer DC, den Elzen WP, Cappola AR, Balmer P, Iervasi G, Åsvold BO, Sgarbi JA, Völzke H, Gencer B, Maciel RM, Molinaro S, Bremner A, Luben RN, Maisonneuve P, Cornuz J, Newman AB, Khaw KT, Westendorp RG, Franklyn JA, Vittinghoff E, Walsh JP, Rodondi N, Thyroid studies collaboration. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med. 2012;172:799–809.CrossRefGoogle Scholar
- 55.Al-Ghamdi AS, Aljohani N. Graves’ thyrotoxicosis-induced reversible cardiomyopathy: a case report. Clin Med Insights Case Rep. 2013;27:47–50.Google Scholar
- 57.Anderson JL, Halperin JL, Albert NM. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations) a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:1935–44.CrossRefGoogle Scholar
- 58.Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, IR cD, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN, American Thyroid Association; American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21:593–646.CrossRefGoogle Scholar